- Home
- CROX vs TMDX Comparison
CROX vs TMDX Comparison
Compare CROX & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CROX | TMDX |
|---|---|---|
| Founded | 1999 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.2B |
| IPO Year | 2006 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CROX | TMDX |
|---|---|---|
| Price | $83.40 | $141.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 8 |
| Target Price | $96.75 | ★ $144.25 |
| AVG Volume (30 Days) | ★ 1.2M | 669.1K |
| Earning Date | 02-12-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 170.70 |
| EPS | ★ 3.26 | 2.54 |
| Revenue | ★ $4,072,780,000.00 | $566,354,000.00 |
| Revenue This Year | N/A | $38.81 |
| Revenue Next Year | N/A | $20.49 |
| P/E Ratio | ★ $26.17 | $56.27 |
| Revenue Growth | 0.01 | ★ 41.20 |
| 52 Week Low | $73.21 | $55.00 |
| 52 Week High | $122.84 | $156.00 |
Technical Indicators
Market Signals| Indicator | CROX | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 42.56 | 64.25 |
| Support Level | $83.95 | $134.00 |
| Resistance Level | $88.25 | $151.85 |
| Average True Range (ATR) | 3.25 | 5.98 |
| MACD | -0.63 | 1.85 |
| Stochastic Oscillator | 5.47 | 68.31 |
Price Performance
Historical ComparisonAbout CROX Crocs Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company are the United States and other Countries.
About TMDX TransMedics Group Inc.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.